about
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancerPhase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapyA multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.Capecitabine in gastric cancer.Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.Combination chemotherapy for metastatic breast cancer.The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients.A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancerThe potential for oral combination chemotherapy of 5'-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancerPhase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.Capecitabine in advanced gastric cancer.Capecitabine in the treatment of advanced gastric cancer.Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review.(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity studyEmerging role of capecitabine in gastric cancer.ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer.Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong.ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.Comparative cytotoxicity of C-1311 in colon cancer in vitro and in vivo using the hollow fiber assay.Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.Capecitabine in the management of colorectal cancer.Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer.A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.Capecitabine as third line therapy in patients with advanced colorectal cancer.Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma.Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer.Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix.Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer.A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer.
P2860
Q28534413-D02F30BA-3938-45AC-8B53-FE81FBB0E4B8Q33364558-DC377645-4B8F-4503-AC4D-F04BFD9D43AEQ33413350-F4E975AB-3B62-4789-935C-5A5A10DE961FQ33631745-DDA4AFA3-0CF0-4AB4-8FDC-25CE785D90B1Q33853588-78FEB241-0073-42F5-B130-F027DDD48BE3Q33903541-F0C6CC8D-AAC6-4750-83C9-005E0D7EC0C3Q34236005-B6CB768D-A870-4EC4-9470-F530073CFFA0Q34608222-38D99F69-3319-4A28-88B5-E842C55CA042Q34734518-A0270A9A-E6C0-4B6E-A014-23D45BEAF95FQ35004485-2BD50104-404A-4E51-9DC1-6DC6976378F6Q35825206-47C258FE-66A7-4B39-A303-2F95649D5B21Q36024905-49378499-6467-49DF-A89E-129B7E226BD2Q36614734-5D2BF6D5-4C74-445D-9DC5-27364A27B82FQ36616002-1D33C6CC-54AE-44C5-B638-05ABBD502AD2Q36646585-1293BB8A-6480-4B58-BE9C-65FF85F629DDQ36671460-F8C422BF-2C95-41F6-B5CD-C011704888D9Q36697132-72C9122D-5DAC-492A-98CB-660EE9C1E2B7Q36979346-5E40251B-E64A-41EC-B751-B8BFA8A129A8Q37136996-DFB27BC5-ABEE-4D7C-BD7C-79D6F34A1D35Q37270388-C605E5A3-4D82-455C-A5B6-1D3EE0849A1DQ37299562-1606F32E-C640-490C-836B-DABA06D2D6DFQ37403462-18A71087-7A15-4165-9177-791EC367F854Q37642780-A25DFAD0-2651-4CE1-94ED-291D2378281AQ38918414-3597C147-32E8-49E3-AAEB-EF33D8137502Q39108105-B6710059-F58D-4A94-A6B0-DB1552C9163BQ39474181-960AF9AC-70D6-4292-854D-4CF56942CD72Q40036736-B31629AA-B533-4590-97F0-F3FE5CD87C50Q40349569-19BBBB4F-6239-43A5-9417-5996FADF4EAAQ43296450-6B44708E-CC1F-4A28-8659-6D7B36036360Q43589273-00D5DE97-AB44-44F6-9409-AE2F2D19590AQ44060826-18F694D1-F41B-4DC8-B82B-39A7F0F20E62Q46378978-4FAB2F92-9BFE-4D22-96E0-D03566F47F28Q46601885-82EFC0E5-46A6-4263-AD5C-2D5D150609B3Q46632076-432BA873-4936-4A4C-BA9B-30D0F92F6066Q46747287-7A801528-6759-4061-8BF9-BE907B4C5EFEQ46813506-AFE87F1E-5A57-4F41-B29C-4B2C3DF686DFQ46862654-1B545597-B046-40E5-94BE-F17F610CC914Q46902871-05C292A0-B38C-485C-8928-C45C0BA80C2AQ51799569-4C6DF872-519F-468A-A769-F3955CE9B56CQ52682114-5F43D146-5248-49D8-A572-662C3EE2F52B
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Capecitabine: preclinical pharmacology studies.
@ast
Capecitabine: preclinical pharmacology studies.
@en
Capecitabine: preclinical pharmacology studies.
@nl
type
label
Capecitabine: preclinical pharmacology studies.
@ast
Capecitabine: preclinical pharmacology studies.
@en
Capecitabine: preclinical pharmacology studies.
@nl
prefLabel
Capecitabine: preclinical pharmacology studies.
@ast
Capecitabine: preclinical pharmacology studies.
@en
Capecitabine: preclinical pharmacology studies.
@nl
P356
P1476
Capecitabine: preclinical pharmacology studies.
@en
P2093
H Ishitsuka
P2888
P304
P356
10.1023/A:1006497231579
P577
2000-11-01T00:00:00Z
P6179
1053363207